Anebulo Pharmaceuticals Inc Total Liabilities
Anebulo Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Anebulo Pharmaceuticals Inc (ANEB) has total liabilities worth $1.49 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of Anebulo Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Anebulo Pharmaceuticals Inc (2020–2025)
Total liabilities of Anebulo Pharmaceuticals Inc from 2020 to 2025. This chart illustrates how Anebulo Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Anebulo Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Anebulo Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OPG POWER VENTURES (OPB.SG)
STU:OPB
|
Germany | €64.61 Million |
|
Malpac Holdings Bhd
KLSE:4936
|
Malaysia | RM8.95 Million |
|
COCRYSTAL PHARMA NEW O.N.
F:8CC
|
Germany | €3.38 Million |
|
Biotechnology Assets S.A.
MC:BST
|
Spain | €7.01 Million |
|
Arcoma AB
ST:ARCOMA
|
Sweden | Skr26.30 Million |
|
Bravada Gold Corporation
V:BVA
|
Canada | CA$1.39 Million |
|
ABERA BIOSCIENCE AB
F:8WK
|
Germany | €7.57 Million |
|
Khind Holdings Bhd
KLSE:7062
|
Malaysia | RM126.37 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Anebulo Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ANEB total assets.
Liquidity & Leverage Metrics
Anebulo Pharmaceuticals Inc Total Liabilities Ratios Explained
Anebulo Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anebulo Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anebulo Pharmaceuticals Inc (2020–2025)
The table below shows the annual total liabilities of Anebulo Pharmaceuticals Inc from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $487.69K | +87.15% |
| 2024-06-30 | $260.58K | -75.62% |
| 2023-06-30 | $1.07 Million | +108.53% |
| 2022-06-30 | $512.53K | +112.11% |
| 2021-06-30 | $241.63K | +7.94% |
| 2020-06-30 | $223.87K | -- |
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical tria… Read more